Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 4/20 | 0.34 |
| ▸ | CA1 | P00915 | 4/20 | 0.34 |
| ▸ | CA2 | P00918 | 4/20 | 0.34 |
| ▸ | CA4 | P22748 | 4/20 | 0.34 |
| ▸ | CA9 | Q16790 | 4/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ECE1 | P42892 | 1/20 | 0.31 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.31 |
| ▸ | GLP1R | P43220 | 3/20 | 0.30 |
| ▸ | EPOR | P19235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23158184 | 1.00 | CRBN (0.38) | CRBNCA12CA1CA2CA4 | |
| SCHEMBL23157563 | 0.93 | CRBN (0.39) | CRBNCA12CA1CA2CA4 | |
| SCHEMBL20883229 | 0.93 | CRBN (0.39) | CRBNCA12CA1CA2CA4 | |
| SCHEMBL20552921 | 0.93 | CRBN (0.39) | CRBNCA12CA1CA2CA4 | |
| SCHEMBL23157517 | 0.93 | CRBN (0.39) | CRBNCA12CA1CA2CA4 | |
| SCHEMBL19437542 | 0.91 | CRBN (0.38) | CRBNCA12CA1CA2CA4 | |
| SCHEMBL26617637 | 0.91 | CRBN (0.37) | CRBNCA12CA1CA2CA4 | |
| SCHEMBL24620135 | 0.90 | CRBN (0.34) | CRBNTTR | |
| SCHEMBL23157910 | 0.90 | CRBN (0.37) | CRBNTTRGLP1REPOR | |
| SCHEMBL23157876 | 0.90 | TSHR (0.38) | CRBNCA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | LYCIA THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | M6PR, ASGR1, IGF2R | CRBN 3454/4885CA12 1621/4885CA1 3431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.